Transcenta Holding names new executive vice president, Global Medicine Development and chief medical officer
8 August 2022 -

Transcenta Holding Limited (HKEX: 06628), a China-based, clinical stage biopharmaceutical company, announced on Sunday that it has named Dr Caroline Germa as its executive vice president, Global Medicine Development and chief medical officer.

Dr Germa is to report to Dr Xueming Qian, CEO. In the new role, Dr. Germa will mainly be responsible for leading the global development and translational research teams to advance the company's pipeline molecules, conducting registrational trials to enable for approval by multiple global regulatory agencies, ensuring safety and compliance and leading the global clinical collaborations with present and potential partners.

Dr Germa has more than 20 years of pharmaceutical experience, across the range of drug development, from early clinical trials to late phase and registration. She has held the position of vice president and head of the Early Development Clinical Group for AstraZeneca oncology department. She has built an Early Development Clinical Group with more than 180 staff and guided the clinical development of the early oncology portfolio. She has served at Bristol Myers Squibb (BMS) and held the position of vice president of BMS Oncology and Development Team Lead for a major partnered oncology program. She has spent seven years at Novartis, and headed the late phase clinical development of various key oncology assets, especially the global registration strategy and approval of Ribociclib (CDK4/6 inhibitor – Kisqali). She has also served Pfizer as its clinical lead for Neratinib (anti-HER2 inhibitor, Nerlynx) and Eli Lilly France and Sanofi/Aventis.